Geoffrey Gottlieb
Basic profileProfessor, Medicine - Allergy and Infectious Diseases · University of Washington
Geoffrey Gottlieb is Professor, Medicine - Allergy and Infectious Diseases at University of Washington. OpenAlex indexes 145 publications with 5,421 citations (h-index 38); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Updated 23 Oct 2026
Geoffrey S. Gottlieb is Professor, Medicine - Allergy and Infectious Diseases at University of Washington. The public record shows 145 publications with 5,423 citations (h-index 38), centered on HIV/AIDS Research and Interventions, HIV Research and Treatment, HIV/AIDS drug development and treatment. It also documents an investigator role on 3 registered clinical trials, 4 NIH-funded awards (2001–2026).
- Most recent indexed publication: 2026 · PLOS global public health
- Top research focus: HIV/AIDS Research and Interventions
- 3 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 91.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1959 NE Pacific St
Seattle, WA 98195-6166
Telephone
206-598-7600Registry record last updated 18 Dec 2018 · collected 28 Jul 2026.
Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- RESIST-2: 2nd-line ART for HIV-2 Infection
Sponsor: University of Washington
- Demonstration Project of PrEP Among Female Sex Workers in Dakar, Senegal
Sponsor: Réseau Africain de Recherche sur le SIDA
- An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Sponsor: University of Washington
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
84.3%Azole Antifungal24.1%Fluconazole100%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor16.9%Dovato100%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
15.7%Proton pump inhibitor15.7%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
4 NIH research awards on record, funded 2001–2026 per NIH RePORTER. The latest:
- Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
University of Washington
FY2026$565,063R01AI120765 - Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
University of Washington
FY2026$185,410R01AI120765 - Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
University of Washington
FY2025$594,778R01AI120765
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- HIV Resistance to Dolutegravir Varies With Coadministered Agents.
Clinical infectious diseases
Article2026 - Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants.
The Journal of infectious diseases
Article2024
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Strongyloidiasis in Transplant PatientsArticle244 citations2009
- 04Dual HIV-1 infection associated with rapid disease progressionArticle198 citations2004
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sph.washington.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sph.washington.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sph.washington.edu ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globalhealth.uw.edu ↗
Secondary affiliations
appointments beyond the home institution- Adjunct Professor
Global Health (University of Washington)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sph.washington.edu ↗ - Medical Director
Environmental Health & Safety Department (EH&S), University of Washington
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sph.washington.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Rainer Storb
University of Washington
Connie Celum, MD, MPH
University of Washington
Helen Chu, MD, MPH
University of Washington
Bryan Kestenbaum, MD
University of Washington
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”